shotsy

What shotsy does

Shotsy is a consumer mobile application purpose-built for patients using GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and oral semaglutide. The iOS and Android app enables users to log weekly injections (or daily oral doses), track weight, nutrition, hydration, and side effects, plan titration schedules, rotate injection sites, and export PDF reports for clinicians. Its distinguishing feature set centers on estimated medication-level visualizations that model pharmacokinetic curves (peaks, valleys, cumulative buildup) and side-effect correlation charts that overlay reported symptoms against dose timing — capabilities not available in general-purpose fitness trackers. The app integrates with Apple Health on iOS and Health Connect on Android, supports 17 languages, and stores user data in private iCloud (iOS) or Google Firebase (Android).

The underlying technology stack is a native cross-platform mobile client with subscription management handled by RevenueCat, crash reporting via Crashlytics, customer support via Zendesk, and aggregated anonymous trend data stored in Supabase. Shotsy's business model is freemium: core tracking features are free, and an annual Premium subscription (recently raised from $29.99 to $49.99/year) unlocks advanced features including multi-medication tracking, dose-coded weight charts, side-effect correlation, maintenance mode, PDF exports, and home-screen widgets. Customer acquisition is entirely organic and community-led through TikTok, Instagram, blog/SEO, and word-of-mouth — the company has not historically spent on paid advertising. The company is headquartered in Portland, Oregon, was founded in 2023 by Aja Beckett (a software engineer and GLP-1 patient), and is venture-backed following a $2.25 million seed round in February 2025 led by Adverb Ventures. Eric Perakslis, former FDA Chief Scientist for Informatics, serves as Chief Science Officer.

Name

shotsy

Legal name

Shotsy Co.

Website

https://shotsyapp.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Shotsy is a freemium iOS and Android mobile app that helps GLP-1 medication patients (Ozempic, Wegovy, Mounjaro, Zepbound) log injections, track side effects and weight, and visualize estimated medication levels. It serves individual consumers globally and monetizes via a $49.99/year Premium subscription.

Ownership category

akta.pro rank

Product category

Consumer Health Tracking Software

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• GLP-1 medication tracking
• Weight loss tracking
• Health monitoring app
• Mobile health tracking
• Medication management

Headquarters

HQ city

Salem

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Premium Subscription: Annual subscription providing access to advanced features including multi-medication support, dose-coded weight charts, medication level charts, side effect correlation, maintenance mode, PDF exports, Apple Health integration, and home screen widgets. Core tracking features are available for free. Price raised from $29.99/year to $49.99/year after seed funding in early 2025.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Shotsy is a freemium mobile application for iOS and Android that lets GLP-1 medication users log weekly injections (or daily oral doses), track side effects, weight, nutrition, and water intake, and visualize estimated medication levels over time. It supports semaglutide and tirzepatide products including Ozempic, Wegovy, Mounjaro, and Zepbound, with a free tier of core tracking features and a Premium subscription unlocking advanced analytics, multi-medication tracking, and PDF exports for healthcare providers.

Product overview

Shotsy is a purpose-built GLP-1 medication tracking mobile app available on iOS (iPhone, iPad, Mac) and Android as a freemium service. The core product is a single unified app (Shotsy GLP-1 Tracker) with a free tier covering core features and a paid Premium tier ($39.99/year) unlocking advanced analytics. The app is built by GLP-1 patients for GLP-1 patients, and helps users log weekly GLP-1 injections (or daily oral medications), track weight, side effects, nutrition, and hydration, visualize estimated medication levels over time, and export PDF reports for healthcare providers. Key differentiating features include dose-coded weight charts, animated interactive medication-level charts spanning multiple time periods, side effect correlation analysis, a dedicated maintenance mode for post-weight-loss tracking, multi-medication simultaneous tracking with combined level views, app themes and accent colors, home screen widgets (estimated medication level widget and countdown widget), and PDF exports for doctors. The app also operates an alternatives comparison section on its website comparing Shotsy against competitor GLP-1 tracking apps (MeAgain, GLPeak, GlucoPal, Pep, and others).

Differentiator

Problem solved

Functional benefit

Products and services

• Shotsy GLP-1 Tracker Mobile application for iOS and Android that lets GLP-1 medication users log weekly injections (or daily oral doses), track side effects, weight, nutrition, and hydration, visualize estimated medication levels over time, and generate PDF reports for healthcare providers. Available as a freemium service with free core tracking and a paid Premium subscription.
• Shotsy GLP-1 Tracker (Android) Android version of the Shotsy GLP-1 Tracker, expanding access to the Shotsy mobile application for Android users via the Google Play Store, with the same GLP-1 dose, side-effect, weight, and medication-level tracking capabilities as the iOS app.
• Shotsy Premium Subscription Annual Premium subscription ($49.99/year, raised from $29.99/year after the February 2025 seed round) that unlocks advanced features of the Shotsy GLP-1 Tracker, including multi-medication simultaneous tracking, dose-coded weight charts, animated interactive medication-level charts, side-effect correlation, maintenance mode, home screen widgets, and PDF reports for healthcare providers.

Quantifiable outcome

• Over 100,000 downloads in approximately 8 months after launch
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature10 records

Partnerships

Three partnerships are on record, tiered core.

• Apple iCloudcoreTechnology or IntegrationiOS users' individual health entries are stored in their private iCloud database associated with their Apple ID. Shotsy does not have access to Apple ID credentials. This is the primary data storage mechanism for iOS users.
• Google FirebasecoreTechnology or IntegrationAndroid app data is stored securely in Google Firebase, enabling sync across devices and account recovery. Users must use Google Sign-In to access the app on Android.
• RevenueCatcoreTechnology or IntegrationRevenueCat manages subscription status and related purchase metadata for unlocking premium features and supporting troubleshooting. Referenced in Shotsy's Terms and Conditions and Privacy Policy.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MeAgain: MeAgain is a direct competitor in the GLP-1 tracking app category. It charges $79.99/year and is explicitly compared against Shotsy on Shotsy's website, indicating overlapping target customers and feature sets.
• GLPeak: GLPeak is a competing GLP-1 focused tracking app listed in Shotsy's comparison content. Targets the same patient persona (GLP-1 users) with overlapping dose, weight, and side-effect tracking features.
• GlucoPal: GlucoPal is a diabetes and GLP-1 tracking app directly competing for the same user base. Listed in Shotsy's competitive comparison pages as an alternative solution.
• Pep (GLP-1 app): Pep is a GLP-1 weight loss tracking app that competes directly with Shotsy for users of Ozempic, Wegovy, Mounjaro, and Zepbound. Same target persona and overlapping feature set.
• Medisafe: Medisafe is a medication adherence and tracking platform that overlaps with Shotsy's core injection logging and reminder functionality. Broader than GLP-1 specifically, but addresses the same patient need for medication tracking.
• MyTherapy: MyTherapy is a medication reminder and health tracking app. It overlaps with Shotsy on dose logging and adherence but is not purpose-built for GLP-1 medications.

Broad incumbents

• MyFitnessPal: MyFitnessPal is a broad nutrition and weight tracking platform that overlaps with Shotsy's weight, calorie, and hydration logging. It is not GLP-1 specific but competes for the same general consumer health-tracking wallet.
• Noom: Noom is a broader weight-management platform with psychological coaching that overlaps with Shotsy's weight-loss user base. Not specialized in GLP-1 but addresses the same demand for weight loss support.
• WW (Weight Watchers): WW is an established incumbent in weight management that competes broadly with Shotsy for weight-loss-focused consumers. Has expanded into GLP-1 support programs, increasing competitive overlap.

Emerging players

• Cronometer: Cronometer is a detailed nutrition and biometric tracking app overlapping with Shotsy's nutrition, water, and weight tracking. Less specialized for GLP-1 but appeals to the same data-driven health-tracking user.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/shotsyapp
• TikToktiktok.com/@shotsyapp
• LinkedInlinkedin.com/company/shotsy

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about shotsy